Aeglea BioTherapeutics Investor Presentation Deck
Aeglea-Spyre Transaction highlights
aeglea
Structure: The acquisition of Spyre was structured as a stock-for-stock transaction whereby all of Spyre's outstanding equity
interests were exchanged for a combination of shares of Aeglea common stock and a newly created non-voting Series A
convertible preferred stock.
SPYRE
THERAPEUTICS
Financing: Concurrent with the acquisition of Spyre, Aeglea closed a $210 million private placement with a group of
institutional accredited investors led by Fairmount Funds and joined by a robust syndicate of dedicated biotechnology
investors as well as additional undisclosed institutional investors.
Primary use of proceeds: The proceeds from the private placement are expected to be primarily used to advance the Spyre
pipeline and deliver the following anticipated milestones: two INDs for SPY001 and SPY002 in 2024, HV PK/PD data for SPY001
in 2H2024, and HV PK/PD data for SPY002 in 1H2025. Proceeds are expected to provide cash runway into 2026.
SPYRE
37View entire presentation